Akèy › Limfòm Non-Hodgkin › Nebraska › Omaha
Etid klinik pou Limfòm Non-Hodgkin nan Omaha, NE
14 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan ak bò kote Omaha (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- University of Nebraska Medical Center, Omaha
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
- The University of Nebraska Medical Center, Omaha
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Ap rekriteFaz 1/2
- Local Institution - 0124, Omaha
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Ap rekriteFaz 2
- Nebraska Cancer Specialists, Omaha
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- University of Nebraska Medical Center, Omaha
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Ap rekriteFaz 1
- University of Nebraska Medical Center, Omaha
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- University of Nebraska Medical Center (UNMC), Omaha
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- University of Nebraska Medical Center, Omaha
Halt Aging in Survivors of Blood Cancers
Ap rekrite
- University of Nebraska Medical Center, Omaha
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Ap rekriteFaz 1/2
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Fred and Pamela Buffett Cancer Center, Omaha
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Ap rekriteFaz 4
- University Of Nebraska Medical Center, Omaha
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Ap rekriteFaz 4
- University Of Nebraska Medical Center, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Omaha
Etid Limfòm Non-Hodgkin nan lòt vil
- New York City, NY31 etid
- Houston, TX31 etid
- Boston, MA26 etid
- Nashville, TN21 etid
- Philadelphia, PA20 etid
- Baldwin Park, CA19 etid
- Washington, DC18 etid
- Chicago, IL18 etid
- Atlanta, GA18 etid
- Milwaukee, WI18 etid
- Columbus, OH18 etid
- Dallas, TX17 etid
Lòt etid nan Omaha
- Kansè pwostat27 etid
- Kansè Poumon ki pa ti selil24 etid
- Kansè nan tete22 etid
- Kansè (tout kalite)18 etid
- Kansè kolorektal18 etid
- Myelom Miltip16 etid
- Kansè ovè14 etid
- Kansè pankreyas14 etid
- Kansè Metastatik13 etid
- Karsinòm selil skuamèz tèt ak kou13 etid
- Ensifizyans kadyak13 etid
- Melanom12 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.